Biotie and Synosia to merge
This article was originally published in Scrip
Biotie Therapies (Finland) is acquiring CNS drug development firm Synosia Therapeutics (Switzerland) in an all-share deal valued at about €94 million based on Biotie's €0.58 per share price at close on 10 January. The merger will generate a combined company with nine clinical-stage drug candidates.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.